RxDoctor Payments Data

Jessica Sanders

Family · Dalton, GANPI 1003231416

Payments from drug & device makers

$2,479in general payments, 2019–2025

Across 87 payments — averaging $28.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$995
  • Dexcom, Inc.$288
  • AbbVie$160
  • Boston Scientific$134
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$132
  • Novo Nordisk$100
  • plus $669 from 23 others

What the payments were for

  • Travel & lodging$61825%
  • Food & beverage$1,81673%
  • Education$452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,479 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$119,138
Medicare patients
556
Services billed
2,069

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban23$10,501
RexultiBrexpiprazole12$9,658
Buprenorphine24$7,266
MovantikNaloxegol Oxalate16$6,982
LinzessLinaclotide12$6,837
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog50$5,551
FiaspInsulin Aspart (Niacinamide)14$4,255
Fiasp FlextouchInsulin Aspart (Niacinamide)21$3,336
ShingrixVaricella-Zoster Ge/As01b/Pf14$2,876
Divalproex Sodium382$2,334
Gabapentin217$1,982
Methenamine Hippurate27$1,573
Tizanidine Hcl120$1,326
Lidocaine11$1,136
Pregabalin86$973

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$10,50123 claims
Otsuka America Pharmaceutical, Inc.Rexulti$26$9,65812 claims
AbbVieLinzess$160$6,83712 claims
Novo NordiskFiasp$100$4,25514 claims
GSKShingrix$19$2,87614 claims
Lilly USA, LLCOlanzapine$41$35424 claims
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$15$27027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in Dalton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →